Vanguard Group Inc Kintara Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.12 Trillion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.14 - $6.8 $94,733 - $4.6 Million
-676,668 Reduced 47.74%
740,814 $80,000
Q4 2021

Feb 14, 2022
BUY
$0.51 - $1.04 $148,679 - $303,190
291,529 Added 25.89%
1,417,482 $723,000
Q3 2021

Nov 12, 2021
BUY
$0.82 - $2.3 $3,052 - $8,560
3,722 Added 0.33%
1,125,953 $969,000
Q2 2021

Aug 13, 2021
BUY
$1.26 - $2.4 $1.41 Million - $2.69 Million
1,122,231 New
1,122,231 $2.55 Million

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email